W
William J. Tremaine
Researcher at Mayo Clinic
Publications - 290
Citations - 26053
William J. Tremaine is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Ulcerative colitis & Inflammatory bowel disease. The author has an hindex of 80, co-authored 282 publications receiving 24233 citations. Previous affiliations of William J. Tremaine include University of Paris & Cedars-Sinai Medical Center.
Papers
More filters
Journal ArticleDOI
Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease.
Murat Törüner,Gavin C. Harewood,Edward V. Loftus,William J. Sandborn,William J. Tremaine,William A. Faubion,Kenneth W. Schroeder,Laurence J. Egan +7 more
TL;DR: The results show that the practice of surveillance colonoscopy varies greatly among endoscopists, and longer procedure duration is significantly associated with the likelihood of dysplasia diagnosis.
Journal ArticleDOI
Concurrent inflammatory bowel disease and myelodysplastic syndromes.
TL;DR: The seemingly high frequency of myelodysplastic syndromes in a large referral-based group of patients with IBD suggests an association; however, an increased risk of MDS was not observed in a small regional cohort of IBD patients.
Journal ArticleDOI
Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10.
Philippe Bulois,William J. Tremaine,Vincent Maunoury,Luc Gambiez,Samira Hafraoui,Emmanuelle Leteurtre,Antoine Cortot,William J. Sandborn,Jean Frétéric Colombel,Pierre Desreumaux +9 more
TL;DR: Histologic lesions of pouchitis are associated with a mucosal imbalance between EL-8 and IL-10, and EL-10 could be proposed as a new treatment for pouchitis.
Journal ArticleDOI
Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients
Jason M. Swoger,Edward V. Loftus,William J. Tremaine,William A. Faubion,Darrell S. Pardi,Sunanda V. Kane,Karen A. Hanson,W. Scott Harmsen,Alan R. Zinsmeister,William J. Sandborn +9 more
TL;DR: Adalimumab was both effective and well tolerated for the treatment of CD in this tertiary practice with a high prevalence of past infliximab exposure, and largely predates FDA approval of adalimumabs for CD.
Journal ArticleDOI
Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity.
Kelvin T. Thia,Kelvin T. Thia,Edward V. Loftus,Darrell S. Pardi,Sunanda V. Kane,William A. Faubion,William J. Tremaine,Kenneth W. Schroeder,Scott Harmsen,Alan R. Zinsmeister,William J. Sandborn +10 more
TL;DR: Granularity, vascular pattern, ulceration, and bleeding‐friability demonstrated good reproducibility and were predictors of the GAES in UC patients, and were significant predictor of overall endoscopic severity.